niclosamide has been researched along with Adenocarcinoma in 4 studies
Niclosamide: An antihelmintic that is active against most tapeworms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p48)
niclosamide : A secondary carboxamide resulting from the formal condensation of the carboxy group of 5-chlorosalicylic acid with the amino group of 2-chloro-4-nitroaniline. It is an oral anthelmintic drug approved for use against tapeworm infections.
Adenocarcinoma: A malignant epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Niclosamide treatment is associated with an inhibitory effect on CRC development and reduced Wnt activity." | 5.43 | The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway. ( Bocuk, D; Klemm, F; Koenig, S; Krause, P; Monin, MB; Niebert, S; Pukrop, T; Stelling, R, 2016) |
| "Niclosamide is an established anti-helminthic drug, which has recently been shown to inhibit the growth of various cancer cells." | 1.56 | Evaluation of the Anti-Tumor Activity of Niclosamide Nanoliposomes Against Colon Carcinoma. ( Hatamipour, M; Jaafari, MR; Momtazi-Borojeni, AA; Ramezani, M; Sahebkar, A, 2020) |
| "Niclosamide is an FDA‑approved anthelmintic drug, and may elicit antineoplastic effects through direct STAT3 inhibition, which has been revealed in numerous human cancer cells." | 1.56 | Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents. ( Chen, YK; Hsu, YJ; Lee, MC; Lin, BR, 2020) |
| "Niclosamide treatment is associated with an inhibitory effect on CRC development and reduced Wnt activity." | 1.43 | The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway. ( Bocuk, D; Klemm, F; Koenig, S; Krause, P; Monin, MB; Niebert, S; Pukrop, T; Stelling, R, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 2 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hatamipour, M | 1 |
| Jaafari, MR | 1 |
| Momtazi-Borojeni, AA | 1 |
| Ramezani, M | 1 |
| Sahebkar, A | 1 |
| Lee, MC | 1 |
| Chen, YK | 1 |
| Hsu, YJ | 1 |
| Lin, BR | 1 |
| Stewart, RL | 1 |
| Carpenter, BL | 1 |
| West, DS | 1 |
| Knifley, T | 1 |
| Liu, L | 1 |
| Wang, C | 1 |
| Weiss, HL | 1 |
| Gal, TS | 1 |
| Durbin, EB | 1 |
| Arnold, SM | 1 |
| O'Connor, KL | 1 |
| Chen, M | 1 |
| Monin, MB | 1 |
| Krause, P | 1 |
| Stelling, R | 1 |
| Bocuk, D | 1 |
| Niebert, S | 1 |
| Klemm, F | 1 |
| Pukrop, T | 1 |
| Koenig, S | 1 |
4 other studies available for niclosamide and Adenocarcinoma
| Article | Year |
|---|---|
Evaluation of the Anti-Tumor Activity of Niclosamide Nanoliposomes Against Colon Carcinoma.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Line, Tumor; Colonic Neoplasms; Doxorubicin; Dr | 2020 |
Niclosamide inhibits the cell proliferation and enhances the responsiveness of esophageal cancer cells to chemotherapeutic agents.
Topics: Adenocarcinoma; Antineoplastic Agents; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; | 2020 |
S100A4 drives non-small cell lung cancer invasion, associates with poor prognosis, and is effectively targeted by the FDA-approved anti-helminthic agent niclosamide.
Topics: A549 Cells; Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Carcinoma, Non-Small-Cell | 2016 |
The anthelmintic niclosamide inhibits colorectal cancer cell lines via modulation of the canonical and noncanonical Wnt signaling pathway.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; beta Catenin; Biomarkers; Biomarkers, Tumor; Blottin | 2016 |